Downloadable Resources
Contact
At Janssen Oncology, we’re shaping the future of cancer treatment. And in the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health.
Janssen Oncology is part of Janssen Biotech, Inc. and the Janssen Pharmaceutical Companies of Johnson & Johnson. As a leading pharmaceutical company in the United States, Janssen focuses its innovation on some of the most devastating diseases and the most complex medical challenges of our time across five therapeutic areas. In addition to Oncology, this includes Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, and Neuroscience.
Janssen’s commitment to providing safe and effective medicines, as well as the services and support that contribute to healthy outcomes, calls for the best science, the most creative minds and an openness to collaborate with researchers, governments and patient organizations at every stage – from early discovery to market access and patient education.
For more information, visit www.janssen.com/us. Follow us on Twitter at www.twitter.com/JanssenUS.
Kyowa Kirin is a global specialty pharmaceutical company with US Headquarters based in Bedminster, NJ. The company is focused primarily on developing and commercializing biopharmaceuticals that help improve the health and well-being of people through innovative and state-of-the-art technologies in various therapeutic areas including oncology, neurology, nephrology, and immunology. For additional information, you can visit us at www.kyowakirin.com.
EUSA Pharma is a dynamic, global biopharmaceutical company focused on oncology and rare disease, continuously striving to confront gaps in patient care. Our ambition drives us to deliver medical treatments that deliver real change to improve lives wherever they are needed in the world. As a young, specialty pharmaceutical company, EUSA Pharma is committed to delivering solutions that can have a meaningful effect on life, helping patients across a range of therapy areas.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States.
Epizyme, Inc. is a fully integrated biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through transformative epigenetic medicines. In addition to a robust research and discovery pipeline, Epizyme has one commercial oncology product and is exploring the treatment potential of this therapy in investigational clinical trials focused on other conditions. By focusing on the genetic drivers of disease, Epizyme works to match new medicines with the patients who need them. For more information, visit www.epizyme.com.
